Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what incentives they are offering to medical partnerships to assist type two diabetes sufferers through research into both stem-cell and non-stem-cell treatments for diabetes type one sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what incentives they are offering to commercial operators to form medical partnerships to advance stem-cell and non-stem-cell treatments for diabetes type one sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to promote international cooperation and joint research to find solutions for both type one and type two diabetes sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what partnerships and expedients they are encouraging to progress diabetes type one stem cell and non-stem-cell research.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is delivering improvements as part of the Vision for the Future of UK Clinical Research Delivery to make the United Kingdom a world leader in clinical research, attracting investment from commercial companies to deliver cutting edge research in a range of disease areas, including diabetes. For example, we introduced the National Contract Value Review to standardise costing and contracting for commercial research in the National Health Service.
This has reduced set up times for clinical research by a third which makes running research in the UK more efficient for commercial companies.
The National Institute for Health and Care Research’s (NIHR) Clinical Research Network (CRN) supports conduct of clinical research in the NHS, providing tailored support for both non-commercial organisations and the life sciences industry. The CRN has a Diabetes Speciality Group to support research across key priorities in diabetes.
The NIHR works in partnership with Diabetes UK to deliver the joint UK Strategy for Clinical and Applied Diabetes Research. The NIHR also funds a Global Health Research Unit on Diabetes and Cardiovascular Disease in South Asia, creating partnerships between research organisations in Bangladesh, India, Pakistan, Sri Lanka and the UK.
Asked by: Christopher Chope (Conservative - Christchurch)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if she will (a) publish average weight to height ratios for children in England and (b) provide advice on any health implications for those who have a ratio significantly larger or smaller than the average.
Answered by Andrea Leadsom - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Child Measurement Programme (NCMP) collects data on the height and weight status of children aged four to five years old, who are in Reception, and 10 to 11 years old, who are in Year six. The data collected and published by NHS England is expressed as a Body Mass Index (BMI) centile, to estimate child overweight and obesity. Data on average weight to height ratios for children in England is not available. The Department does not plan to publish data on average weight to height ratios, or average waist to height ratios for children in England. Waist measurements are not collected as part of the NCMP.
The clinical guidance from the National Institute of Health and Care Research recommends that a waist to height ratio measurement is considered alongside a child’s BMI centile in individual clinical assessments, to give a practical estimate of central adiposity. If a child falls into an unhealthy weight category, a waist to height ratio will give additional health information in clinical settings. This includes helping to assess and predict individual health risks such as type 2 diabetes, hypertension, or cardiovascular disease, as the location of where children carry weight on their bodies has an influence on their health.
Asked by: Earl of Dundee (Conservative - Excepted Hereditary)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what steps they are taking to find solutions for diabetes type one sufferers.
Answered by Lord Markham - Parliamentary Under-Secretary (Department of Health and Social Care)
The goal of treating type 1 diabetes is to keep blood glucose within a healthy range by providing the body with supplemental insulin. The National Health Service, with the Department’s support, has taken a number of steps to help manage type 1 diabetes.
In line with the commitments in the NHS Long Term Plan, NHS England is driving access to new and existing technologies such as continual glucose monitors. This reflects the essential role that technology plays in allowing individuals with type 1 diabetes to manage their blood sugars correctly and avoid dangerous complications. Furthermore, maternity services across the country are now offering continuous glucose monitors to expectant mothers with type 1 diabetes.
Finally, approximately 72% of children and young people living with type 1 diabetes have registered with the Digibete app, which helps users manage their type 1 diabetes. Over 250,000 unique users have accessed the open access adult website, with over 3,800 education modules undertaken.
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether her Department is taking steps to increase uptake in the use of monitoring technologies by patients with diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has recently issued clinical guidelines in relation to the management of insulin dependent diabetes, covering patients living with type 1 and insulin dependent type 2 diabetes. This includes devices to support blood glucose monitoring. These recommendations are now being implemented by integrated care boards (ICBs).
On 19 December 2023, NICE published its final recommendation on the hybrid closed loop system for people with type 1 diabetes. NICE has agreed with NHS England that all children and young people, women who are pregnant or planning a pregnancy, and those people who already have an insulin pump will be first to be offered a hybrid closed loop system as part of a 5-year roll-out plan. NHS England has set out priorities for access, to help reduce healthcare inequalities through their implementation plan.
Responsibility for the delivery of services and the implementation of NICE recommendations rests with the appropriate National Health Service commissioner. As diabetes care is commissioned by local ICBs, they are responsible for developing commissioning policies. ICBs must pay due regard to NICE guidance, however local decision making applies in terms of deciding whether to utilise their funding to implement the recommendation or not.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help prevent cases of type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The NHS Diabetes Prevention Programme identifies people at risk of developing type 2 diabetes, and refers them to a nine-month lifestyle change programme, which has been proven to reduce a person’s risk of developing type 2 diabetes by 37%.
The NHS Health Check is England’s flagship cardiovascular disease prevention programme, which is offered to eligible people aged 40 to 74 years old, and includes an assessment for type 2 diabetes. If an individual is found to be at risk of type 2 diabetes, they are referred on to their general practice for further clinical assessment, treatment if appropriate, or further referred to programmes such as the National Diabetes Prevention Programme, to help reduce their risk of developing type 2 diabetes.
Asked by: Layla Moran (Liberal Democrat - Oxford West and Abingdon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps she is taking to help ensure the adequacy of short-term supplies of the diabetes medication Ozempic or semaglutide.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
Following intensive work with industry, the broad supply position for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the United Kingdom has improved. However, global supply issues remain with specific medicines, including ozempic (semaglutide). We issued updated guidance to healthcare professionals in the form of a National Patient Safety Alert on 3 January 2024, on how to manage patients requiring these medicines, with input from expert clinicians. We continue to work closely with manufacturers and others working in the supply chain to help ensure the continued supply of GLP-1 RAs for UK patients, and to resolve the remaining supply issues as quickly as possible, for example by asking suppliers to expedite deliveries.
We know how distressing and frustrating medicine supply issues can be, and the Department will continue to help ensure that these critical medicines reach diabetes patients. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.
Asked by: Martyn Day (Scottish National Party - Linlithgow and East Falkirk)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 February 2024 to Question 15459 on Diabetes: Medical Equipment, what the evidential basis is for growth in the prescribing of diabetes technology for people living with type 2 diabetes.
Answered by Andrew Stephenson - Minister of State (Department of Health and Social Care)
The National Institute for Care and Excellence (NICE) published a recommendation in March 2023 that people with type 2 diabetes, who have multiple daily insulin injections and a condition or disability that means they cannot use capillary blood glucose monitoring, should be offered Continuous Glucose Monitoring (CGM) technology, either real time or intermittent, to support self-monitoring.
The NICE also recommended in March 2023 that adults with insulin-treated type 2 diabetes having their blood glucose monitored by a care worker or healthcare professional, are offered CGM. The rationale is that CGM can help to improve glycaemic control in adults with type 2 diabetes who use insulin.